Abzena, an end-to-end integrated CDMO + CRO for complex biologics and bioconjugates, has appointed Moncef Slaoui, PhD, to its ...

Enhancing its peptide synthesis capabilities to meet increasing demand from its global partners for efficient and scalable ...

Esphera SynBio, a pre-clinical stage synthetic biology company, has launched a new project aimed at enhancing the efficacy of ...

With over $410 million in financing; to advance portfolio of next-gen oral and injectable treatments with first- or ...

Excipient GMP certification validates the company's quality systems and process controls to support the cell and gene therapy ...

A Phase 2 trial of MTX-463 in idiopathic pulmonary fibrosis expected in 1H 2025.